DAPK1

Death-associated protein kinase 1 · P53355 · DAPK1 on Sugi Atlas →

13,736 patent compounds predicted against DAPK1, 10,963 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Kaempferol (SCHEMBL18817)	1.00	4/20
Myricetin (SCHEMBL19302)	1.00	4/20
Quercetin (SCHEMBL19723)	1.00	4/20
Morin (SCHEMBL19984)	1.00	4/20
Quercetin (SCHEMBL118425)	1.00	4/20
Quercetin (SCHEMBL22103)	0.97	4/20
Morin (SCHEMBL294933)	0.97	4/20
Quercetin (SCHEMBL288466)	0.92	4/20
Myricetin (SCHEMBL1064954)	0.92	4/20
Quercetin (SCHEMBL1148195)	0.90	4/20
Galangin (SCHEMBL117225)	0.81	4/20
Datiscetin (SCHEMBL43916)	0.78	4/20
Herbacetin (SCHEMBL872691)	0.76	4/20
Quercetin (SCHEMBL729498)	0.76	4/20
SCHEMBL360758	0.72	4/20
Quercetagetin (SCHEMBL554527)	0.72	4/20
Kaempferol (SCHEMBL731179)	0.68	4/20
SCHEMBL117527	0.67	4/20
SCHEMBL120585	0.65	4/20
SCHEMBL1160941	0.60	4/20

Clinical trials — most relevant to DAPK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer	PHASE4	UNKNOWN
Minocycline for the Treatment of Early-Phase Schizophrenia	PHASE3	COMPLETED
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma	PHASE3	COMPLETED
A Cohort Study of Beta-Glucan or Beta-Glucan Compound in Metastatic Cancers	PHASE2/PHASE3	UNKNOWN
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity	PHASE2	RECRUITING
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer	PHASE1/PHASE2	COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma	PHASE2	UNKNOWN
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
Baricitinib Compared to Standard Therapy in Patients With COVID-19	PHASE2	UNKNOWN
Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers	PHASE1/PHASE2	UNKNOWN
Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]	PHASE2	UNKNOWN
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection	PHASE2	NOT_YET_RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy	PHASE1	UNKNOWN
Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer	PHASE1	UNKNOWN
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study	PHASE1	UNKNOWN
Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer	PHASE1	WITHDRAWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Effect of Severe Trauma on PD1 and Its Legend (PD1/L1) on T Lymphocytes and Correlation With Mortality	nan	UNKNOWN
Limb RIPC in Patients Undergoing Lung Lobectomy. Study of Oxidative Lung Damage	nan	COMPLETED
The Role of Neutrophil CD64 and Soluble Triggering Receptor Expressed on Myeloid Cells 1 in Neonatal Sepsis	nan	UNKNOWN
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)	nan	NOT_YET_RECRUITING
Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma	nan	RECRUITING
Evaluation of Serum Gasdermin D Level As a Potential Biomarker of Disease Activity in Vitiligo Patients	nan	UNKNOWN
Autophagy, Oxidative Stress and Hippo Signaling in Human Aortic Aneurysm	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DAPK1 binder may also engage these)

Protein	Name	Similarity
Q80YE7	—	1.000	Q80YE7 →
O44997	—	1.000	O44997 →
P11730	—	0.994	P11730 →
B4NBB0	—	0.994	B4NBB0 →
P54936	—	0.994	P54936 →
Q7T163	—	0.993	Q7T163 →
B0XDC4	—	0.993	B0XDC4 →
Q6DEH3	—	0.993	Q6DEH3 →
Q54Y55	—	0.992	Q54Y55 →
Q9H1H9	—	0.992	Q9H1H9 →
Q9ULH0	—	0.992	Q9ULH0 →
Q8BHI9	—	0.992	Q8BHI9 →
P25799	—	0.992	P25799 →
Q54RB7	—	0.992	Q54RB7 →
Q9M8S6	—	0.991	Q9M8S6 →
Q8NDG6	—	0.991	Q8NDG6 →
B2RR83	—	0.991	B2RR83 →
F4IS56	—	0.991	F4IS56 →
Q9TZC4	—	0.991	Q9TZC4 →
Q86AT8	—	0.991	Q86AT8 →
Q95266	—	0.991	Q95266 →
INPP5B	Type II inositol 1,4,5-trisphosphate 5-phosphatase	0.991	landscape →
B4LX81	—	0.991	B4LX81 →
Q9BGT9	—	0.991	Q9BGT9 →
P52332	—	0.990	P52332 →
CAMK2D	Calcium/calmodulin-dependent protein kinase type II subunit delta	0.990	landscape →
Q6E0V2	—	0.990	Q6E0V2 →
PRKCD	Protein kinase C delta type	0.990	landscape →
Q6DGS3	—	0.990	Q6DGS3 →
Q5SNQ7	—	0.990	Q5SNQ7 →